Swanson Reed News

Budget 2019: R&D Tax Incentive Programme Cost Reductions with No Specific Detail

April 3rd, 2019

The Federal Government handed down their budget on 2 April 2019 and whilst there appeared to be no specific new changes proposed to the R&D Tax Incentive, the forward estimates cost of the programme is projected to reduce by $1.35 billion. It is not clear whether this cost reduction is a product of: The legislative changes proposed in the last federal budget being introduced. These changes were recently the subject of a Senate Economics Committee review that recommended the changes […]

Read More

AIIA Says R&D Tax Incentive Is Crucial For Australian AI Development

March 29th, 2019

The Australian Information Industry Association (AIIA) has stated that government, industry and researchers must work together to ensure solutions are developed for potential opportunities and issues posed by artificial intelligence (AI) products and services. Chief Executive Ron Gauci said that a focus on skills development and an effective R&D Tax Incentive programme would encourage a more favourable business environment for innovation, commercialisation and export of Australian AI products. He said that without strong government support, Australia will struggle to compete […]

Read More

CBA Settlement of Disputed Claims for Software R&D Activities

March 18th, 2019

CBA have announced to the ASX on 18 March that they have entered into a settlement in respect of a tax dispute regarding the eligibility of claims for software development R&D activities. Below is an extract from the ASX announcement: Commonwealth Bank of Australia has agreed to withdraw from all current proceedings with the ATO and Innovation and Science Australia (ISA) before the AAT in respect of the eligibility of R&D claims that were made for the years ended 30 […]

Read More

Australia’s Attractiveness for Clinical Trials

March 6th, 2019

To bring a new drug to market, an average of 12 years and $1.7 billion (US) in R&D spending is required. Yet only 1 in 5,000 drugs that begin preclinical testing make it to the market. This has led to a disproportionate number of drugs being developed for rare diseases (affecting less than 200,000 in the US at any given time) due to a 25.3% success rate versus 3.4% for oncology. Many argue this is unsustainable and there is pressure […]

Read More

Bryce Steele
Principal, Melbourne
Tel: (03) 9018 5778
Mob: 0435 713 493
Tom Parkhouse
Principal, Sydney
Tel: (02) 8006 0559
Mob: 0411 718 565
Andy Nguyen
Principal, Brisbane
Tel: (07) 3221 1499
Mob: 0407 750 249
Kieu McKellar
Manager, Adelaide
Tel: (08) 8121 7850
Mob: 0435 713 493
David Greatwich
Principal, Perth
Tel: (08) 9340 3745
Mob: 0468 386 250
Sarah Guan
Manager, Hobart
Tel: (03) 9018 5778
Mob: 0401 262 591

Categories

Archives

Email this job

[recaptcha]